Phase 3 Readout
SUPN: Phase 3 Topline: Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of SPN-812 for the Treatmen
September 1, 2026 · attention-deficit. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 1, 2026
- Company
- SUPERNUS PHARMACEUTICALS, INC. (SUPN)
- Drug
- attention-deficit
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of SPN-812 for the Treatmen
- Drug
- attention-deficit
- Indication
- Attention-Deficit/Hyperactivity Disorder